Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC]

Xuan Ying Poh, I Russel Lee, Clarissa Lim, Jefanie Teo, Suma Rao, Po Ying Chia, Sean W X Ong, Tau Hong Lee, Ray J H Lin, Lisa F P Ng, Ee Chee Ren, Raymond T P Lin, Lin-Fa Wang, Laurent Renia, David Chien Lye, Barnaby E Young, Xuan Ying Poh, I Russel Lee, Clarissa Lim, Jefanie Teo, Suma Rao, Po Ying Chia, Sean W X Ong, Tau Hong Lee, Ray J H Lin, Lisa F P Ng, Ee Chee Ren, Raymond T P Lin, Lin-Fa Wang, Laurent Renia, David Chien Lye, Barnaby E Young

Abstract

Background: Over 2021, COVID-19 vaccination programs worldwide focused on raising population immunity through the primary COVID-19 vaccine series. In Singapore, two mRNA vaccines (BNT162b2 and mRNA-1273) and the inactivated vaccine CoronaVac are currently authorized under the National Vaccination Programme for use as the primary vaccination series. More than 90% of the Singapore population has received at least one dose of a COVID-19 vaccine as of December 2021. With the demonstration that vaccine effectiveness wanes in the months after vaccination, and the emergence of Omicron which evades host immunity from prior infection and/or vaccination, attention in many countries has shifted to how best to maintain immunity through booster vaccinations.

Methods: The objectives of this phase 3, randomized, subject-blinded, controlled clinical trial are to assess the safety and immunogenicity of heterologous boost COVID-19 vaccine regimens (intervention groups 1-4) compared with a homologous boost regimen (control arm) in up to 600 adult volunteers. As non-mRNA vaccine candidates may enter the study at different time points depending on vaccine availability and local regulatory approval, participants will be randomized at equal probability to the available intervention arms at the time of randomization. Eligible participants will have received two doses of a homologous mRNA vaccine series with BNT162b2 or mRNA-1273 at least 6 months prior to enrolment. Participants will be excluded if they have a history of confirmed SARS or SARS-CoV-2 infection, are immunocompromised, or are pregnant. Participants will be monitored for adverse events and serious adverse events by physical examinations, laboratory tests and self-reporting. Blood samples will be collected at serial time points [pre-vaccination/screening (day - 14 to day 0), day 7, day 28, day 180, day 360 post-vaccination] for assessment of antibody and cellular immune parameters. Primary endpoint is the level of anti-SARS-CoV-2 spike immunoglobulins at day 28 post-booster and will be measured against wildtype SARS-CoV-2 and variants of concern. Comprehensive immune profiling of the humoral and cellular immune response to vaccination will be performed.

Discussion: This study will provide necessary data to understand the quantity, quality, and persistence of the immune response to a homologous and heterologous third booster dose of COVID-19 vaccines. This is an important step in developing COVID-19 vaccination programs beyond the primary series.

Trial registration: ClinicalTrials.gov NCT05142319 . Registered on 2 Dec 2021.

Keywords: Antibodies; COVID-19; Immunogenicity; Phase 3; Randomized controlled trial; SARS-CoV-2; Vaccine booster.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2022. The Author(s).

References

    1. Doria-Rose N, Suthar MS, Makowski M, O'Connell S, McDermott AB, Flach B, et al. Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for COVID-19. N Engl J Med. 2021;384(23):2259–2261. doi: 10.1056/NEJMc2103916.
    1. Thomas SJ, Moreira ED, Jr, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine through 6 months. N Engl J Med. 2021;385(19):1761–1773. doi: 10.1056/NEJMoa2110345.
    1. CDC. Science Brief: Emerging SARS-CoV-2 Variants. . Accessed 04 Mar 2022.
    1. Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021;596(7871):276–280. doi: 10.1038/s41586-021-03777-9.
    1. Chia WN, Zhu F, Ong SWX, Young BE, Fong SW, Le Bert N, et al. Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. Lancet Microbe. 2021;2(6):e240–e2e9. doi: 10.1016/S2666-5247(21)00025-2.
    1. Planas D, Saunders N, Maes P, Guivel-Benhassine F, Planchais C, Buchrieser J, et al. Considerable escape of SARS-CoV-2 omicron to antibody neutralization. Nature. 2022;602(7898):671–5.
    1. Garcia-Beltran WF, St Denis KJ, Hoelzemer A, Lam EC, Nitido AD, Sheehan ML, et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 omicron variant. Cell. 2022;185(3):457–66 e4.
    1. Schmidt F, Muecksch F, Weisblum Y, Da Silva J, Bednarski E, Cho A, et al. Plasma neutralization of the SARS-CoV-2 omicron variant. N Engl J Med. 2022;386(6):599–601.
    1. Dejnirattisai W, Huo J, Zhou D, Zahradnik J, Supasa P, Liu C, et al. SARS-CoV-2 omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell. 2022;185(3):467–84 e15. doi: 10.1016/j.cell.2021.12.046.
    1. Callaway E. COVID vaccine boosters: the most important questions. Nature. 2021;596(7871):178–180. doi: 10.1038/d41586-021-02158-6.
    1. Tenbusch M, Schumacher S, Vogel E, Priller A, Held J, Steininger P, et al. Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2. Lancet Infect Dis. 2021;21(9):1212–1213. doi: 10.1016/S1473-3099(21)00420-5.
    1. Lu S. Heterologous prime-boost vaccination. Curr Opin Immunol. 2009;21(3):346–351. doi: 10.1016/j.coi.2009.05.016.
    1. He Q, Mao Q, An C, Zhang J, Gao F, Bian L, et al. Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates. Emerg Microbes Infect. 2021;10(1):629–637. doi: 10.1080/22221751.2021.1902245.
    1. Liu J, Xu K, Xing M, Zhuo Y, Guo J, Du M, et al. Heterologous prime-boost immunizations with chimpanzee adenoviral vectors elicit potent and protective immunity against SARS-CoV-2 infection. Cell Discov. 2021;7(1):123. doi: 10.1038/s41421-021-00360-4.
    1. Liu X, Shaw RH, Stuart ASV, Greenland M, Aley PK, Andrews NJ, et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (com-COV): a single-blind, randomised, non-inferiority trial. Lancet. 2021;398(10303):856–869. doi: 10.1016/S0140-6736(21)01694-9.
    1. Li W, Li X, Zhao D, Liu J, Wang L, Li M, et al. Heterologous prime-boost with AdC68- and mRNA-based COVID-19 vaccines elicit potent immune responses in mice. Signal Transduct Target Ther. 2021;6(1):419. doi: 10.1038/s41392-021-00843-6.
    1. Agrati C, Capone S, Castilletti C, Cimini E, Matusali G, Meschi S, et al. Strong immunogenicity of heterologous prime-boost immunizations with the experimental vaccine GRAd-COV2 and BNT162b2 or ChAdOx1-nCOV19. NPJ Vaccines. 2021;6(1):131. doi: 10.1038/s41541-021-00394-5.
    1. Brown SA, Surman SL, Sealy R, Jones BG, Slobod KS, Branum K, et al. Heterologous prime-boost HIV-1 vaccination regimens in pre-clinical and clinical trials. Viruses. 2010;2(2):435–467. doi: 10.3390/v2020435.
    1. Mogus AT, Liu L, Jia M, Ajayi DT, Xu K, Kong R, et al. Virus-like particle based vaccines elicit neutralizing antibodies against the HIV-1 fusion peptide. Vaccines (Basel). 2020;8(4):765.
    1. Palgen JL, Feraoun Y, Dzangue-Tchoupou G, Joly C, Martinon F, Le Grand R, et al. Optimize prime/boost vaccine strategies: trained immunity as a new player in the game. Front Immunol. 2021;12:612747. doi: 10.3389/fimmu.2021.612747.
    1. Ella R, Reddy S, Blackwelder W, Potdar V, Yadav P, Sarangi V, et al. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. Lancet. 2021;398(10317):2173–2184. doi: 10.1016/S0140-6736(21)02000-6.
    1. Renia L. Durable T cell responses contrast with faster antibody waning in BNT162b2-vaccinated elderly at 6 month. 10.21203/-1103804/v1. In press 09 Dec 2021.
    1. Montecino-Rodriguez E, Berent-Maoz B, Dorshkind K. Causes, consequences, and reversal of immune system aging. J Clin Invest. 2013;123(3):958–965. doi: 10.1172/JCI64096.
    1. Lawton G. You're only as young as your immune system. New Sci. 2020;245(3275):44–48. doi: 10.1016/S0262-4079(20)30646-1.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit